- In May 2025, Amneal Pharmaceuticals received FDA approval for a generic version of Tobramycin and Dexamethasone ophthalmic suspension (0.3%/0.1%), therapeutically equivalent to TobraDex. This combination is used to treat steroid-responsive inflammatory ocular conditions with a risk of superficial bacterial infection. The approval strengthens Amneal’s ophthalmic portfolio and provides a more affordable option for patients needing dual-action anti-inflammatory and antibiotic treatment
- In November 2024, Novartis AG announced it had increased production of its Tobramycin-based eye drops due to surging demand across Asia-Pacific, especially for post-surgical prophylaxis and conjunctivitis treatment. The company’s expansion is part of its commitment to improving accessibility to essential ophthalmic medications Source – Novartis Press Releases
- In August 2024, Bausch Health Companies Inc. launched a new preservative-free Tobramycin ophthalmic solution in the U.S., targeting patients with hypersensitivity or chronic use needs. This innovation enhances patient safety by reducing the risk of preservative-induced irritation while maintaining antibacterial efficacy Source – Business Wire
- In June 2024, Zydus Lifesciences Ltd. received regulatory approval in India for a fixed-dose combination of Tobramycin and Fluorometholone, expanding its ophthalmology product line. The product targets dual-action treatment for inflammation and bacterial infections post-surgery or injury. Source – Zydus Lifesciences Newsroom
